GRAIL, Inc., a healthcare company focused on early cancer detection, announced progress in the regulatory review process for its Galleri® multi-cancer early detection (MCED) test. The company is in the midst of a Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA) under a Breakthrough Device Designation. The submission is modular, with GRAIL anticipating completion in the first half of 2026. The PATHFINDER 2 study results, demonstrating enhanced cancer detection and safety, will be part of this application. Additionally, bridging analyses comparing different versions of Galleri will be included. There were no safety concerns reported in the study, further supporting the test's reliability.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。